BGLC - Company ID 0001737523
BioNexus Gene Lab Corp trades as BGLC. In its fiscal 2025 annual report the company posted revenue of $7.42M, down 21.9% from the prior year and net income of -$2.98M. This page tracks BioNexus Gene Lab Corp through 140 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 7 fiscal years BioNexus Gene Lab Corp's revenue grew from $212.33K to $7.42M, a compound annual growth rate of 66.2%. Net profit margin compressed from 12.5% to -40.2% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-15 |
| Annual report | 10-K | 2026-04-14 |
| NT 10-K | - | 2026-03-31 |
| Major company event | 8-K | 2026-03-17 |
| Major company event | 8-K | 2026-02-23 |
| Major company event | 8-K | 2026-02-03 |
| Major company event | 8-K | 2025-12-30 |
| Major company event | 8-K | 2025-12-23 |
The largest companies sharing BioNexus Gene Lab Corp's SEC industry classification (services-medical laboratories).
BioNexus Gene Lab Corp reported revenue of $7.42M for fiscal year 2025, a decrease of 21.9% year over year.
In its latest fiscal year BioNexus Gene Lab Corp reported a net loss of $2.98M.